NCT03478995
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy
Key Eligibility Criteria:
Gender: All
Age: 19 Years and older (Adult, Senior)
Location of Metastases:
Additional Notes:
Exclusions: Untreated, active, or progressing CNS metastases, or active CNS metastases requiring treatment- see trial for details
https://ClinicalTrials.gov/show/NCT03478995